- PharmaScience, the largest Canadian-owned pharmaceutical company, has expanded its Contract Development and Manufacturing services, creating a new business unit dedicated to injectable products.
PharmaScience, the Canadian-owned pharmaceutical company, has announced a significant expansion of its Contract Development and Manufacturing Organisation (CDMO) services. This expansion follows the company’s recent $120 million sterile injectable manufacturing facility expansion at its Canadian site.
The company has created a new business unit dedicated to injectable products. This new business unit will help accelerate production and achieve PharmaScience’s growth objectives. It will focus more specifically on injectable products, offering CDMO services to biotech companies and those with complex injectable product development or manufacturing needs.
Martin Arès, CEO of PharmaScience, said, “With a vision to continue our expansion while supporting local development and manufacturing, we see a tremendous opportunity to expand our services to meet the needs of a growing pharmaceutical client base.” He added that the new CDMO business unit represents an excellent way to maximise the value of their research and development efforts.
Overview of outsourcing trends 
